Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.
On Dec. 1, Travere Therapeutics will have a new CEO for the first time in almost eight years, as Eric Dube hands the baton to ...
Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...
Clinical Trials Arena on MSN
Roche targets Novartis on IgAN market after Phase III win
Novartis gained approval of a drug in IgAN with the same target as Roche’s sefaxersen in 2026.
Ligand Pharmaceuticals agreed to provide up to $47 million in financing to AvenCell Therapeutics to support oncology drug ...
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Patent Application No. 19/253,120, titled ...
Travere Therapeutics (NasdaqGM:TVTX) announced a planned CEO and President transition effective December 1, 2026. Dr. Eric ...
Travere Therapeutics has announced that Bradley L. Campbell will become President and Chief Executive Officer on December 1, 2026, succeeding Eric Dube, Ph.D., who has decided to step down after ...
Travere Therapeutics has delivered a very large share price gain over the past few years, which naturally puts the focus on ...
Ligand agreed to acquire royalty and milestone rights for Santen’s Ryjunea eye drop for $23 million upfront, expanding its ...
Eric Dube, Ph.D., the CEO who rebranded Travere Therapeutics and oversaw the launch of its rare kidney disease drug Filspari, will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results